Videos

These late-breaking data on drug candidate ENV-101 were presented at ATS 2024 and resulted from a new study on the drug’s effect on individuals with IPF.

James R. Kilgore, DMSc, PhD, PA-C, discusses a new primary care screening tool for cognitive decline, plus lifestyle interventions that may complement drugs.

Beth Browning, PA-C, LPC, provides advice for busy primary care providers to efficiently incorporate timely and treatment-initiating depression screening.

Fortman reviews the state of the 2021 AHA/ACC guideline recommendations to pursue shared decision making and cost-efficient testing strategies.

Kilgore reviews early cognitive decline tools include AD8 and MoCA, and how they should be utilized at the primary care level.

Bludorn reviews preventive measures and strategic collaboration to ensure high-risk patients for conditions like heat stroke are identified before an acute event occurs.

An AAPA 2024 session reflected on the joint AHA/ACC chest pain guidelines, particularly the adoption of high-density troponin level testing since 2021.

During AAPA 2024, a group of session presenters provide recommendations for the next year's agenda based on trends and development.

Peterson reviews the gastric and hormonal events linked to drugs like tirzepatide, before considering whether incretin therapies will help to finally embrace obesity as the medical condition it is.

With incidence climbing amid climate change, an emergency medicine doctor has advice on prevention of cardiovascular and dermatologic effects.

With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.

From the prospect of semaglutide and MDMA for substance use disorder to evolving research around personality disorders and OCD, here are 5 key topics from the annual psychiatric meeting.

During this interview segment, Alexis was asked how trifarotene, in combination with an appropriate skincare routine, addresses post-inflammatory hyperpigmentation in skin of color.

This interview featured a discussion of Alexis’s team’s findings on the importance of treating patients with skin of color and acne-induced post-inflammatory hyperpigmentation.

Oldham highlights the anticipated change to a more dimensional perspective on personality disorders in new guidelines anticipated later this year.

In this interview segment, Rigotti discussed the way in which cytisinicline can help adults to quit e-cigarettes and the future of her team’s research on this product.

Sibille and colleagues have made progress in refining the therapeutic pathways of Alzheimer disease. Human trials may soon follow.

This discussion covered the topic of e-cigarette use and its potential treatment with cytisinicline, a plant-based medication which may aid vapers in quitting.

McIntyre discusses how GLP-1 and GIP receptor agonists like semaglutide could potentially improve both acute and long-term measures of psychiatric disease.

At ARVO 2024, Roger Goldberg, MD explores the greater reductions in hard exudates achieved with faricimab than aflibercept in eyes with DME.

At ARVO 2024, Deepayan Kar, MD, PhD, describes the potential of measuring contrast sensitivity function using a novel gaze tracking-based VR headset in AMD.

Robert O. Cotes, MD, discusses why the proven agent clozapine may still be underutilized in schizophrenia.

Daniel Su, MD describes the promise of APX3330 for delaying or preventing diabetic retinopathy progression in a post-hoc analysis of the ZETA-1 trial.

Daniela Ferrara, MD, PhD described the key takeaways from the machine learning model's performance in predicting outcomes for various treatment durations of faricimab in DME.

During this interview segment, Browning highlighted the impact of a future FDA acceptance of tapinarof for atopic dermatitis as well as the next milestones in regulatory approval.

At ARVO 2024, Ashkan Abbey, MD describes key data from the pivotal OAKS and DERBY, and the GALE extension trial over 3 years of pegcetacoplan treatment.

In this Lungcast episode segment, Balmes spoke about advocating for air pollution improvements, inequities in air quality, and more.

The utility of second-generation antipsychotics and clozapine has been less advantageous than it could be, Kane explained.

In this interview, Browning discusses his team’s trial data and the implications of the FDA’s decision to accept the supplemental new drug application for tapinarof as an eczema treatment.

McIntyre explains why GLP-1/GIP receptor agonists like semaglutide may alter cognitive and psychiatric care similar to cardiometabolic disease.